Chlorogenic Acid Decreases Malignant Characteristics of Hepatocellular Carcinoma Cells by Inhibiting DNMT1 Expression.
DNMT1
chlorogenic acid
hepatocellular carcinoma
migration
proliferation
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
12
2019
accepted:
26
05
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the adult liver, exhibiting rapid progression and poor prognosis. Chlorogenic acid (CGA), a polyphenol, has several biological activities, including the suppression of liver cancer cell invasion and metastasis. Increased levels or alterations in the function of DNMT1 are associated with the inactivation of tumor suppressor genes. However, the CGA-affected DNMT1 expression mediated mechanism is still unclear. The human hepatocellular carcinoma (HCC) HepG2 cells were treated with a positive control drug (5-AZA) or varying doses of CGA. DNA methyltransferase 1 (DNMT1) protein levels and other relevant proteins were evaluated using Western blotting and immunocytochemistry. Cell-cycle analysis was performed by flow cytometry-based PI staining, and cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The transwell invasion and wound healing assays were used to evaluate cell migration and invasion. In vivo proliferation of the HCC cells was detected. We investigated the expression of DNMT1, p53, p21, p-ERK, MMP-2, and MMP-9 in tumors using immunohistochemical analysis. Our results showed that CGA inhibited the proliferation, colony formation, invasion, and metastasis of HepG2 cells both CGA can suppress liver cancer cell proliferation, invasion, and metastasis through several pathways. CGA could serve as a candidate chemopreventive agent for HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the adult liver, exhibiting rapid progression and poor prognosis. Chlorogenic acid (CGA), a polyphenol, has several biological activities, including the suppression of liver cancer cell invasion and metastasis. Increased levels or alterations in the function of DNMT1 are associated with the inactivation of tumor suppressor genes. However, the CGA-affected DNMT1 expression mediated mechanism is still unclear.
METHODS
METHODS
The human hepatocellular carcinoma (HCC) HepG2 cells were treated with a positive control drug (5-AZA) or varying doses of CGA. DNA methyltransferase 1 (DNMT1) protein levels and other relevant proteins were evaluated using Western blotting and immunocytochemistry. Cell-cycle analysis was performed by flow cytometry-based PI staining, and cell viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The transwell invasion and wound healing assays were used to evaluate cell migration and invasion. In vivo proliferation of the HCC cells was detected. We investigated the expression of DNMT1, p53, p21, p-ERK, MMP-2, and MMP-9 in tumors using immunohistochemical analysis.
RESULTS
RESULTS
Our results showed that CGA inhibited the proliferation, colony formation, invasion, and metastasis of HepG2 cells both
CONCLUSIONS
CONCLUSIONS
CGA can suppress liver cancer cell proliferation, invasion, and metastasis through several pathways. CGA could serve as a candidate chemopreventive agent for HCC.
Identifiants
pubmed: 32655395
doi: 10.3389/fphar.2020.00867
pmc: PMC7325898
doi:
Types de publication
Journal Article
Langues
eng
Pagination
867Informations de copyright
Copyright © 2020 Liu, Feng, Li, Hu, Zhang, Huang, Shi, Ran, Hou, Zhou and Wang.
Références
Trends Mol Med. 2017 Apr;23(4):310-319
pubmed: 28279624
Hypertens Res. 2012 Apr;35(4):370-4
pubmed: 22072103
Clin Exp Metastasis. 2000;18(2):111-20
pubmed: 11235986
Inflamm Res. 2010 Oct;59(10):871-7
pubmed: 20405164
Curr Genomics. 2011 Apr;12(2):130-7
pubmed: 21966251
World J Gastroenterol. 2014 Jan 14;20(2):333-45
pubmed: 24574704
Oncogene. 2005 Apr 18;24(17):2899-908
pubmed: 15838523
Curr Opin Genet Dev. 1996 Feb;6(1):56-64
pubmed: 8791491
J Nutr Biochem. 2017 Aug;46:68-73
pubmed: 28458139
Crit Rev Food Sci Nutr. 2009 Jun;49(6):538-51
pubmed: 19484634
J Biol Chem. 2005 Jul 29;280(30):27888-95
pubmed: 15944151
Oncogene. 2018 Nov;37(44):5829-5842
pubmed: 29973691
Clin Epigenetics. 2016 Apr 30;8:46
pubmed: 27134688
Nat Rev Genet. 2002 Jun;3(6):415-28
pubmed: 12042769
Afr J Tradit Complement Altern Med. 2012 Oct 01;10(1):53-9
pubmed: 24082326
Avicenna J Phytomed. 2014 Jan;4(1):1-14
pubmed: 25050296
Int J Mol Sci. 2018 May 19;19(5):
pubmed: 29783729
Nutr Cancer. 2011;63(7):1044-52
pubmed: 21888504
Phytomedicine. 2012 May 15;19(7):625-30
pubmed: 22397993
J Nutr Biochem. 2013 Nov;24(11):1911-9
pubmed: 24011717
Eur J Pharmacol. 2009 Nov 25;623(1-3):119-24
pubmed: 19786014
J Ovarian Res. 2018 May 14;11(1):39
pubmed: 29759079
Curr Cancer Drug Targets. 2005 Jun;5(4):285-98
pubmed: 15975049
Arq Neuropsiquiatr. 2007 Dec;65(4B):1114-22
pubmed: 18345413
Trends Cell Biol. 1996 Oct;6(10):388-92
pubmed: 15157521
Int J Mol Sci. 2015 Mar 17;16(3):6124-39
pubmed: 25789501
Clin Cancer Res. 2009 Aug 15;15(16):5026-31
pubmed: 19671858
Gastroenterology. 1996 Sep;111(3):720-6
pubmed: 8780578
Oncogene. 2002 Aug 12;21(35):5483-95
pubmed: 12154409
Adv Exp Med Biol. 2016;945:123-150
pubmed: 27826837
J Nutr Biochem. 2012 Oct;23(10):1249-55
pubmed: 22209001
Nature. 2000 Nov 16;408(6810):307-10
pubmed: 11099028
Inflamm Res. 2013 Jun;62(6):581-7
pubmed: 23483217
J Cell Physiol. 2019 Aug;234(8):12910-12917
pubmed: 30536843
Genes Dev. 2013 Feb 15;27(4):372-7
pubmed: 23431054